CORDIS
EU research results

CORDIS

English EN
Stem Cells for Relevant Efficient Extended and Normalized Toxicology

Stem Cells for Relevant Efficient Extended and Normalized Toxicology

Objective

In the development of products for use by humans it is vital to identify compounds with toxic properties at an early stage of their development, to avoid spending time and resource on unsuitable and potentially unsafe candidate products. Human pluripotent stem cell lines offer a unique opportunity to develop a wide variety of human cell-based test systems because they may be expanded indefinitely and triggered to differentiate into any cell type. SCR&Tox aims at making use of these two attributes to provide in vitro assays for predicting toxicity of pharmaceutical compounds and cosmetic ingredients. The consortium has been designed to address all issues related with biological and technological resources to meet that goal. In order to demonstrate the value of pluripotent stem cells for toxicology, the consortium will focus on four complementary aspects: Relevance –i.e. establishing and maintaining discrete cell phenotypes over long-term cultures; providing large versatility to adapt to assays of specific pathways. Efficiency –for i) automated cell production and differentiation, ii) cell engineering for differentiation and selection iii) multi-parametric toxicology using functional genomic, proteomic and bioelectronics. Extension –i.e. i) scalability through production of cells and technologies for industrial-scale assays, and ii) diversity of phenotypes (5 different tissues), and of genotypes (over 30 different donors). Normalization –validation and demonstration of reproducibility and robustness of cell-based assays on industrial-scale platforms, to allow for secondary development in the pharmaceutical and cosmetic industry. SCR&Tox will be intricately associated to other consortia of the “Alternative Testing” call, sharing biological, technological and methodological resources. Proof of concept of the proposed pluripotent stem cell-based assays for toxicology will be provided on the basis of toxicity pathways and test compounds identified by other consortia.

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Address

Rue De Tolbiac 101
75654 Paris

France

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 101 929,33

Administrative Contact

Laurie Louis-Joseph (Mrs.)

Participants (14)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITAETSKLINIKUM BONN

Germany

EU Contribution

€ 399 218

Takara Bio Europe AB

Sweden

EU Contribution

€ 612 269

CELLECTIS SA

France

EU Contribution

€ 171 030,56

CXR Biosciences Limited

United Kingdom

EU Contribution

€ 237 205,77

UNIVERSITAET LEIPZIG

Germany

EU Contribution

€ 293 322,88

CIT SAS

France

EU Contribution

€ 236 858,94

COVANCE LABORATORIES LTD

United Kingdom

EU Contribution

€ 236 576,35

JRC -JOINT RESEARCH CENTRE- EUROPEAN COMMISSION

Belgium

EU Contribution

€ 313 426,65

ASTRAZENECA AB

Sweden

EU Contribution

€ 226 936,70

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 267 996,96

AVANTEA srl

Italy

EU Contribution

€ 155 570

Public Health England an Executive Agency of the Dept of Health

United Kingdom

EU Contribution

€ 119 454,18

INSERM TRANSFERT SA

France

EU Contribution

€ 160 800

Department of Health

United Kingdom

EU Contribution

€ 167 404,68

Project information

Grant agreement ID: 266753

Status

Closed project

  • Start date

    1 January 2011

  • End date

    31 December 2015

Funded under:

FP7-HEALTH

  • Overall budget:

    € 9 400 000

  • EU contribution

    € 4 700 000

Coordinated by:

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France